John Farnam - Kura Oncology COO
| KURA Stock | USD 17.53 0.15 0.85% |
COO
Mr. John Farnam is the Chief Operating Officer of Kura Oncology Inc. He has served as our Chief Operating Officer since July 2018. From September 2015 to June 2018 Mr. Farnam served as Vice President of Business Operations at Receptos, Inc., a privatelyheld biopharmaceutical company and a subsidiary of Celgene, Inc., where his responsibilities included clinical operations, quality assurance, finance, facilities and professional leadership development. Previously, Mr. Farnam served for 26 years as an officer in the Marine Corporationration, including serving as the Commanding Officer of Marine Corporationration Air Station Miramar from July 2012 to August 2015 where he oversaw operations of the air station and its 2, 500 personnel, and prior to that as an FA18D Squadron Commanding Officer. Mr. Farnam retired from the Marine Corporationration as a Colonel in 2015 since 2018.
| Age | 50 |
| Tenure | 6 years |
| Address | 12730 High Bluff Drive, San Diego, CA, United States, 92130 |
| Phone | 858 500 8800 |
| Web | https://kuraoncology.com |
Kura Oncology Management Efficiency
The company has return on total asset (ROA) of (0.229) % which means that it has lost $0.229 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3734) %, meaning that it created substantial loss on money invested by shareholders. Kura Oncology's management efficiency ratios could be used to measure how well Kura Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -0.36. The current year's Return On Capital Employed is expected to grow to -0.38. At present, Kura Oncology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 454.1 M, whereas Return On Tangible Assets are forecasted to decline to (0.36).Similar Executives
| Found 5 records | COO Age | ||
| Harry Jordan | Cogent Biosciences | 49 | |
| Don Patrick | Cogent Biosciences | 56 | |
| Matthew Winton | Inozyme PharmaInc | 46 | |
| MBA II | Day One Biopharmaceuticals | 47 | |
| Eben Tessari | Kiniksa Pharmaceuticals | 42 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.23 |
Kura Oncology Leadership Team
Elected by the shareholders, the Kura Oncology's board of directors comprises two types of representatives: Kura Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kura. The board's role is to monitor Kura Oncology's management team and ensure that shareholders' interests are well served. Kura Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kura Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Stein, Director | ||
| Mollie MD, Executive Development | ||
| Francis Burrows, Senior Research | ||
| Roger Bakale, Clinical CMC | ||
| Thomas Malley, Director | ||
| Marc MD, Advisor | ||
| Mary Szela, Director | ||
| John Farnam, COO | ||
| Thomas Doyle, Principal Accounting | ||
| Esq JD, Chief Sec | ||
| MS MBA, Chief Officer | ||
| Kirsten Flowers, Chief Officer | ||
| Pingda Ren, Sr. VP of Chemistry and Pharmaceutical Sciences | ||
| Heidi Henson, CFO, Secretary | ||
| Troy Wilson, Chairman of the Board and Presidentident, CEO, Co-Founder | ||
| Kathleen Ford, Chief Officer | ||
| JD Esq, Chief Secretary | ||
| Stephen MD, Chief Officer | ||
| Faheem Hasnain, Independent Director | ||
| Annette North, Senior Vice President General Counsel | ||
| Liu Yi, Co-Founder, Chief Scientific Officer | ||
| Troy JD, CEO, Chairman | ||
| Antonio Gualberto, Chief Medical Officer | ||
| Marc Grasso, CFO and Chief Business Officer | ||
| Pete Spain, Executive Communications | ||
| Robert Hoffman, Independent Director | ||
| Maureen MBA, VP Management |
Kura Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kura Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 962.95 M | ||||
| Shares Outstanding | 76.18 M | ||||
| Shares Owned By Insiders | 1.75 % | ||||
| Shares Owned By Institutions | 98.25 % | ||||
| Number Of Shares Shorted | 10.41 M | ||||
| Price To Earning | (9.03) X | ||||
| Price To Book | 3.73 X | ||||
| EBITDA | (164.96 M) |
Kura Oncology Investors Sentiment
The influence of Kura Oncology's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kura. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Kura Oncology's public news can be used to forecast risks associated with an investment in Kura. The trend in average sentiment can be used to explain how an investor holding Kura can time the market purely based on public headlines and social activities around Kura Oncology. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Kura Oncology's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Kura Oncology's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Kura Oncology's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Kura Oncology.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kura Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kura Oncology's short interest history, or implied volatility extrapolated from Kura Oncology options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Return On Assets (0.23) | Return On Equity (0.37) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.